U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07805759) titled 'Daydrop(R) Triple Action for Allergic Eye Symptoms' on Sept. 01.
Brief Summary: The study is designed to evaluate the safety and efficacy of Daydrop(R) Triple Action for the symptomatic treatment of seasonal or perennial allergic conjunctivitis. It is a prospective, post-market clinical investigation using a quasi-experimental before-and-after design with intra-subject control.
Daydrop(R) Triple Action is an ophthalmic solution containing ectoine, hyaluronic acid, and carboxymethylcellulose, developed to hydrate, lubricate, and protect the ocular surface, helping to relieve symptoms such as itching, redness, tearing, and foreign bo...